3D structure of large molecules for rational drug design
This technique employs single crystal X-ray diffraction (SXRD) to unambiguously determine the three dimensional structure of large biological molecules. Pharmaceutical and biotechnology researchers need to understand how disease is controlled at the molecular level within proteins and related macromolecules so as to target specific entities based on this knowledge. A prerequisite for this approach is the ability to obtain a high-resolution 3D molecular structure of the macromolecule under investigation. Given the importance of this research, Rigaku has been at the forefront in the development of a wide range of instrumentation related to various aspects of macromolecular crystallography.
In medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are discovered and designed. In the recent past, most drugs have been discovered either by identifying the active ingredient from traditional remedies or by serendipitous discovery. A new approach, using so-called "rational drug design", has been to understand how disease and infection are controlled at the molecular and physiological level and to target specific entities based on this knowledge. Given this importance, Rigaku has been at the forefront in the development of single crystal diffraction for both macromolecular and small molecule structure determination. Our products range from automated crystallization and crystal imaging through crystal diffraction screening and high-resolution data collection systems to 3D structure refinement and imaging software.